High-throughput lymphocyte reaction assays take time, skilled scientists, and cutting-edge laboratory instrumentation. Partnering with our specialists for immunogenicity compound screening will help you progress quickly and make informed decisions for the next step of your project.

 

Why should I consider the Mixed Lymphocyte Reaction assay for my project?

The MLR constitutes a reactivity test that measures the cell microenvironment reaction to a drug indicating how the compound would interact with the body. Drug developers also use this assay to test the efficacy of cancer immunotherapies, vaccines, and other therapeutics that potentially increase, decrease, or repolarize the interaction between T cells and the antigen-presenting cells.

 

What is a Mixed Lymphocyte Reaction assay?

The MLR assay is a platform for testing compounds that modify the interaction between an antigen-presenting cell and T cells to activate, deactivate or repolarize the lymphocyte cell response. This assay allows testing the efficacy of immunotherapeutic, vaccines, and other immunomodulators. It also provides critical information for immunological responsiveness for drug safety.

 

Horizon's standard MLR assay

Our one-way MLR assay enables rapid identification of drugs that regulate T cell activation via allogenic monocyte-derived dendritic cells (Mo-DC). We test your biologics or small molecules at semi-automated high throughput screening in an immune in vitro microenvironment context.

The T lymphocytes cells will proliferate in the presence of Antigen-Presenting Cells (APC) from a different donor. The human leukocyte antigen (HLA) mismatch between two unrelated donors stimulates the T cells' immune response, inducing them to proliferate. When proteins on the surface of T cells recognize and bind to companion proteins on other cells, immune checkpoints are activated. These checkpoint pathways engage when a T cell binds to a professional APC cell, such as a dendritic cell (DC).

 

Key advantages

  • Semi-automated and reproducible 384-well high throughput assay
  • Providing concise and robust quantitative data
  • Highly enriched human primary T cells and Mo-DC from multiple donors to address donor-to-donor variability
Figure 1b
In-vitro derived dendritic cells from peripheric blood CD14+ monocytes obtained from a mix of donors co-cultured with CD3+ lymphocytes from different donors

In the co-culture, the added compound of interest at several concentrations allows the analysis of the drug's effect in the immune synapse by analyzing the effect in multiple cell types (CD4+ and CD8+ T cells) and IFN-gamma secretion. We also measured the percentage of proliferated T cells by flow cytometry (see reference 2).

Read-outs generated by experts

  • Multiple surface markers, cell proliferation and cytokine release to clearly understand the immuno-modulatory profile of your drug candidates
  • Dose-response curves plus vehicle control including control compounds